Colorectal Cancer Clinical Trial
Official title:
First Line Infusional 5-Fluorouracil, Folinic Acid and Oxaliplatin for Metastatic Colorectal Cancer or Loco-Regional Recurrency - Role of Chronomodulated Delivery Upon Survival - A Multicenter Randomized Phase III Trial
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Combining more than one drug may kill more tumor cells. It is
not yet known which regimen of combination chemotherapy is more effective in treating
patients with recurrent or metastatic colorectal cancer.
PURPOSE: Randomized phase III trial to study the effectiveness of combining fluorouracil,
leucovorin, and oxaliplatin in different ways in treating patients with recurrent or
metastatic colorectal cancer.
OBJECTIVES: I. Compare the effects of chronomodulated versus nonchronomodulated infusional
administration of a 3 drug high-dose chemotherapy regimen on survival in patients with
locoregionally recurrent or metastatic colorectal cancer. II. Assess the antitumor effect of
the combination of fluorouracil, leucovorin calcium, and oxaliplatin given as first line
chemotherapy in these patients. III. Assess the response rate and toxicity of this treatment
in these patients. IV. Assess the quality of life of patients receiving this treatment.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
performance status (ECOG 0-1 vs 2), extent of liver involvement (none vs less than 25% vs
25% or greater), and institution. Patients are randomized into 2 arms: Arm I
(chronotherapy): Patients receive a 4 day infusion of fluorouracil, leucovorin calcium, and
oxaliplatin administered via pump using chronomodulated delivery rates. Arm II (fixed
infusion rate): Patients receive leucovorin calcium and oxaliplatin as 2 hour concurrent
infusions followed by fluorouracil as a 22 hour infusion on day 1. On day 2, patients
receive a 2 hour infusion of leucovorin calcium followed by a 22 hour infusion of
fluorouracil. For patients on both arms, courses repeat every 2 weeks until the occurrence
of disease progression, severe toxicity, or complete remission for a minimum of 4 months.
Quality of life is assessed prior to treatment and 2 weeks after courses 4 and 8. Patients
are followed for survival.
PROJECTED ACCRUAL: A total of 554 patients will be accrued for this study.
;
Allocation: Randomized, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
| Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
| Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
| Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
| Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
| Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
| Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
| Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
| Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
| Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |